GRAIL (NASDAQ:GRAL) Announces Quarterly Earnings Results

by · The Markets Daily

GRAIL (NASDAQ:GRAL – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10, FiscalAI reports. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The company had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million.

Here are the key takeaways from GRAIL’s conference call:

  • Galleri sales continued to grow: Second-quarter screening revenue rose 24% year over year to $42.6 million, while test volume increased 35% to more than 61,000. The company added approximately 1,000 ordering providers and said growth is coming from brick-and-mortar physicians, digital health partners, employers, and payer partnerships.
  • FDA review remains on track: GRAIL expects an FDA advisory committee meeting in fall 2026 and continues to anticipate potential approval in the first part of 2027. Management said the PMA review is progressing through an iterative process and that it is preparing for the advisory committee.
  • Clinical data showed strong detection and safety metrics: Management highlighted false-positive rates below 0.5%, positive predictive values of 50% to 60%, and substantially higher cancer detection when Galleri was added to standard screening. The company also emphasized that roughly 40% to 50% of detected cancers were stage I or II, although the NHS-Galleri trial did not meet its primary endpoint for reducing stage III and IV cancers.
  • Samsung financing supports international expansion: GRAIL completed a $110 million strategic investment from Samsung and began planning commercialization in South Korea, with potential expansion to Japan and Singapore. Management said discussions around distribution and longer-term collaboration are just beginning.
  • Investment and pricing pressures remain: Adjusted EBITDA loss widened 15% year over year to $90.3 million, while average selling price declined because of greater digital-health volume and lower employer pricing. An Illumina royalty expected to resume toward the end of the fourth quarter will also create a future margin headwind, though management expects minimal Q4 impact.

GRAIL Trading Up 2.0%

GRAL traded up $1.48 on Wednesday, reaching $74.18. 507,070 shares of the company traded hands, compared to its average volume of 511,078. GRAIL has a one year low of $29.95 and a one year high of $118.84. The firm has a fifty day simple moving average of $66.97 and a two-hundred day simple moving average of $66.72.

Insider Transactions at GRAIL

In related news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares of the company’s stock, valued at $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.83% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GRAIL

Several institutional investors and hedge funds have recently bought and sold shares of the company. Farallon Capital Management LLC raised its stake in shares of GRAIL by 73.7% in the fourth quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after purchasing an additional 993,684 shares during the last quarter. State Street Corp raised its holdings in GRAIL by 38.8% in the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after purchasing an additional 510,546 shares during the period. Morgan Stanley increased its stake in shares of GRAIL by 63.8% during the fourth quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after purchasing an additional 588,647 shares in the last quarter. Alyeska Investment Group L.P. purchased a new position in GRAIL in the 4th quarter valued at $37,874,000. Finally, RA Capital Management L.P. acquired a new position in shares of GRAIL during the 4th quarter worth approximately $36,655,000.

Analyst Ratings Changes

A number of analysts have commented on GRAL shares. Wolfe Research initiated coverage on GRAIL in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. TD Cowen reaffirmed a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Robert W. Baird set a $70.00 target price on GRAIL in a research report on Wednesday, May 6th. Finally, Piper Sandler boosted their target price on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, GRAIL presently has an average rating of “Hold” and a consensus price target of $67.78.

Read Our Latest Research Report on GRAIL

About GRAIL

(Get Free Report)

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.

Further Reading